104 related articles for article (PubMed ID: 38942581)
1. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Rheum Dis Clin North Am; 2024 Aug; 50(3):483-518. PubMed ID: 38942581
[TBL] [Abstract][Full Text] [Related]
2. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Clin Geriatr Med; 2022 May; 38(2):397-432. PubMed ID: 35410687
[TBL] [Abstract][Full Text] [Related]
3. The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
Oo WM; Little C; Duong V; Hunter DJ
Drug Des Devel Ther; 2021; 15():2921-2945. PubMed ID: 34262259
[TBL] [Abstract][Full Text] [Related]
4. The current state of the osteoarthritis drug development pipeline: a comprehensive narrative review of the present challenges and future opportunities.
Kim H; Seo J; Lee Y; Park K; Perry TA; Arden NK; Mobasheri A; Choi H
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221085952. PubMed ID: 36504595
[TBL] [Abstract][Full Text] [Related]
5. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs).
Oo WM; Hunter DJ
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090297. PubMed ID: 35619876
[TBL] [Abstract][Full Text] [Related]
6. Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
Eckstein F; Le Graverand MP
Semin Arthritis Rheum; 2015 Dec; 45(3):251-6. PubMed ID: 26142321
[TBL] [Abstract][Full Text] [Related]
7. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics.
Oo WM; Yu SP; Daniel MS; Hunter DJ
Expert Opin Emerg Drugs; 2018 Dec; 23(4):331-347. PubMed ID: 30415584
[TBL] [Abstract][Full Text] [Related]
8. Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment.
Jotanovic Z; Mihelic R; Sestan B; Dembic Z
Curr Drug Targets; 2014 Jun; 15(6):635-61. PubMed ID: 24597569
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
[TBL] [Abstract][Full Text] [Related]
10. Current Models for Development of Disease-Modifying Osteoarthritis Drugs.
Makarczyk MJ; Gao Q; He Y; Li Z; Gold MS; Hochberg MC; Bunnell BA; Tuan RS; Goodman SB; Lin H
Tissue Eng Part C Methods; 2021 Feb; 27(2):124-138. PubMed ID: 33403944
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic therapy for osteoarthritis--the era of disease modification.
Hunter DJ
Nat Rev Rheumatol; 2011 Jan; 7(1):13-22. PubMed ID: 21079644
[TBL] [Abstract][Full Text] [Related]
12. Anticytokine therapy for osteoarthritis: evidence to date.
Malemud CJ
Drugs Aging; 2010 Feb; 27(2):95-115. PubMed ID: 20104937
[TBL] [Abstract][Full Text] [Related]
13. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?
Qvist P; Bay-Jensen AC; Christiansen C; Dam EB; Pastoureau P; Karsdal MA
Pharmacol Res; 2008 Jul; 58(1):1-7. PubMed ID: 18590824
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in intra-articular drug delivery systems for osteoarthritis therapy.
Maudens P; Jordan O; Allémann E
Drug Discov Today; 2018 Oct; 23(10):1761-1775. PubMed ID: 29792929
[TBL] [Abstract][Full Text] [Related]
15. Osteoarthritis phenotypes and novel therapeutic targets.
Van Spil WE; Kubassova O; Boesen M; Bay-Jensen AC; Mobasheri A
Biochem Pharmacol; 2019 Jul; 165():41-48. PubMed ID: 30831073
[TBL] [Abstract][Full Text] [Related]
16. Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs.
Gao J; Xia Z; Mary HB; Joseph J; Luo JN; Joshi N
Trends Pharmacol Sci; 2022 Mar; 43(3):171-187. PubMed ID: 35086691
[TBL] [Abstract][Full Text] [Related]
17. Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis.
Li J; Wang X; Ruan G; Zhu Z; Ding C
Expert Opin Investig Drugs; 2021 Sep; 30(9):923-930. PubMed ID: 34427483
[TBL] [Abstract][Full Text] [Related]
18. Prospects for Therapies in Osteoarthritis.
Ghouri A; Conaghan PG
Calcif Tissue Int; 2021 Sep; 109(3):339-350. PubMed ID: 32055890
[TBL] [Abstract][Full Text] [Related]
19. DMOAD developments: present and future.
Pelletier JP; Martel-Pelletier J
Bull NYU Hosp Jt Dis; 2007; 65(3):242-8. PubMed ID: 17922676
[TBL] [Abstract][Full Text] [Related]
20. Biomaterial strategies for improved intra-articular drug delivery.
Mancipe Castro LM; García AJ; Guldberg RE
J Biomed Mater Res A; 2021 Apr; 109(4):426-436. PubMed ID: 32780515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
